Prof. Dr. med. Hartmut Döhner
Department of Internal Medicine III
In recent years, there has been enormous progress in characterizing genetic drivers in leukemogenesis, followed by the successful clinical development of molecular therapies. Collaborative Research Center (CRC) 1074 has anticipated and accompanied this development from the very beginning. CRC 1074 has aimed at bridging basic, translational and (pre)clinical research in the field of leukemia, focusing on translating insights into the pathogenesis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) into new therapies.
The CRC 1074 is built upon one of the central research themes of Ulm University and a long-standing tradition in hematology with one of the first CRCs of the DFG (“Zellsystem-Physiologie”) addressing issues of normal and aberrant hematopoiesis and the first allogeneic hematopoietic-cell transplantations, in both children and adults, performed in Germany. CRC 1074 is also based on most visible clinical research in leukemia and unique biobanks for AML and CLL, belonging to the largest clinically and molecularly annotated collections worldwide. To this end, the close association of CRC 1074 with clinical study groups such as the German AML Study Group (AMLSG) and the German CLL Study Group (DCLLSG) as well as the Pediatric I-BFM group has been a major asset. The contribution of CRC 1074 to the genetic characterization and the development of novel therapies for acute and chronic leukemias is highlighted by several seminal publications. Also, CRC 1074 groups have made major contributions to preclinical models of leukemia and the characterization of normal and aberrant development in hematopoesis.
In this third funding period, CRC 1074 shall again undergo dynamic changes by the integration of new projects and by implementing new technologies, for example taking into account developments in single-cell sequencing technology and epigenetic profiling. The Steering Committee succeeded in integrating two research groups from the German Cancer Research Center in Heidelberg, and one group from Charité University Medicine Berlin, based on their specific expertise and on already long-standing collaborations.
Thus, CRC 1074 provides a superb opportunity to realize the concept of translational research in acute and chronic leukemias. We expect that this third funding period will further successfully strengthen the international visibility of leukemia research at Ulm University and continue to provide major scientific contributions. The invaluable resources of CRC 1074 will facilitate translating research findings into clinical practice and ultimately improve care of patients with leukemia.
Third funding period for leukemia Collaborative Research Center:
DFG supports Ulm cancer research with 11 million Euros. Read more
Ulmer Krebsforscher geehrt
Professor Dr. Hartmut Döhner erhählt zwei hohe internationale Auszeichnungen. Mehr lesen
Chronisch Lymphatische Leukämie: Neuer therapeutischer Ansatz den Krebszellen die zelloläre Unterstützung entziehen. Mehr lesen
Scientists at Ulm University among world's 'Highly Cited Researchers' 2019
Prof. Hartmut Döhner and Prof. Stephan Stilgenbauer among them. Read more
Heisenberg-Professur für Pamela Fischer-Posovszky
Fettgewebe verstehen, um Übergewicht zu bekämpfen. Mehr lesen
White Paper des Deutschen Stammzellnetzwerkes
Der steinige Weg in die klinische Anwendung. Mehr lesen
Meileinstein auf dem Weg zur Professorin
Ulmer Forscherinnen in das Wrangell-Habilitationsprogramm aufgenommen, darunter Dr. Julia Zinngrebe. Mehr lesen
"Highly Cited Researchers" 2018
Neun Uni-Forscher unter den weltweit einflussrechsten - unter ihnen Prof. Hartmut Döhner und Prof. Stephan Stilgenbauer. Mehr lesen
Department of Internal Medicine III
* Due to the current global situation, seminars and events have been put on hold until further notice *